Showing 2691-2700 of 5974 results for "".
- JAK Kinase Inhibitors Show Promise in Treating Alopeciahttps://practicaldermatology.com/news/jak-kinase-inhibitors-show-promise-in-treating-alopecia/2459947/UPDATED -- New research suggests selective oral JAK kinase inhibitors may play a role in treating moderate-to-severe alopecia areata (AA). The findings were presented at the Inflammatory Skin Disease Summit in Vienna, Austria. In this
- Modernizing Medicine Introduces New Patient Engagement Toolshttps://practicaldermatology.com/news/modernizing-medicine-introduces-new-patient-engagement-tools/2459951/Modernizing Medicine has launched enhanced patient engagement tools powered by Relatient that are designed to reduce no-shows and improve patient compliance, satisfaction, and operational efficiency. Patients who do not show for appointments can be a significant cost and ef
- New Study Seeks to Improve Skin Cancer Prevention in Young Adults Via a New Websitehttps://practicaldermatology.com/news/new-study-seeks-to-improve-skin-cancer-prevention-in-young-adults-via-a-new-website/2457539/Researchers out of Rutgers Cancer Institute of New Jersey and colleagues from across the country are conducting a study to evaluate the reach and effectiveness of an online program targeted at skin cancer prevention in young adults. Investigators are refining an existing website to
- Dermatologists Need More Info About Cannabinoidshttps://practicaldermatology.com/news/dermatologists-need-more-info-about-cannabinoids/2457549/Dermatologists are interested in learning more about cannabinoids and recommending them to patients, according to a new survey in Journal of Drugs in Dermatology. However, many are concerned about th
- Asana Biosciences Gets Fast Track Designation from FDA for Dual JAK/SYK Inhibitor for ADhttps://practicaldermatology.com/news/asana-biosciences-gets-fast-track-designation-from-fda-for-dual-jaksyk-inhibitor-for-ad/2457550/The FDA has granted Fast Track designation to Asana BioSciences’ investigational oral Janus Kinase (JAK) and Spleen Tyrosine Kinase (SYK) dual inhibitor ASN002 for the treatment of moderate-to-severe atopic dermatitis. “We are pleased that the FDA has granted Fast Track
- Encore Dermatology Announces Phase 2 Safety Data for Impoyzhttps://practicaldermatology.com/news/encore-dermatology-announces-phase-2-safety-data-for-impoyz/2457496/A Phase 2, open-label study published in SKIN The Journal of Cutaneous Medicine, found that subjects treated with Impoyz (clobetasol propionate) Cream, 0.025% showed significantly lower mean post-treatment clobetasol propionate plasma concentrations versus the subjects treated with Temov
- LEO, PellePharm Form Collaboration Focused on Innovationhttps://practicaldermatology.com/news/leo-pellepharm-form-collaboration-focused-on-innovation/2457501/A new strategic development and commercialization collaboration between LEO Pharma and PellePharm is intended to address unmet medical needs across various skin diseases with no approved treatments, the parties say. The collaborators seek to advance innovation and access to potential therapies fo
- PRP Improves Skin Tone, Wrinkleshttps://practicaldermatology.com/news/prp-improves-skin-tone-wrinkles/2457511/Platelet-rich plasma (PRP) reduces the signs of aging on the face, according to the first randomized study of PRP. In the trial, 19 participants received PRP injections to one side of their face and a sham treatment with a saline solution to the other side. Six months afte
- Study: Fine Water Particle Sprays Improve Facial Skin Moisture for Hourshttps://practicaldermatology.com/news/study-fine-water-particle-sprays-improve-facial-skin-moisture-for-hours/2457515/Spraying fine water particles onto the face in winter, when skin is dry, improved skin hydration and softening, according to a new study in Skin Research & Technology. In addition, water retention remained co
- Endo's CCH Improves Appearance of Cellulite in Buttockshttps://practicaldermatology.com/news/endos-cch-improves-appearance-of-cellulite-in-buttocks/2457516/Endo International plc’s clostridium histolyticum (CCH) performed well in two identical Phase 3 studies for the treatment of cellulite in the buttocks. Subjects receiving CCH showed highly statistically significant levels of improvement in the appearance of cellulite with treatment,